Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 20/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21428998 | 0.83 | ERN1 (0.57) | ERN1TLR2TLR1TLR6 | |
| SCHEMBL21428496 | 0.78 | ERN1 (0.61) | ERN1 | |
| SCHEMBL29673738 | 0.78 | ERN1 (0.61) | ERN1 | |
| SCHEMBL11301276 | 0.76 | ABL1 (0.54) | — | |
| SCHEMBL28513847 | 0.76 | NPC1 (0.57) | ERN1 | |
| SCHEMBL21428581 | 0.76 | NPC1 (0.57) | ERN1 | |
| SCHEMBL21411483 | 0.75 | ERN1 (0.66) | ERN1 | |
| SCHEMBL29673772 | 0.75 | ERN1 (0.66) | ERN1 | |
| SCHEMBL21411482 | 0.75 | ERN1 (0.66) | ERN1 | |
| SCHEMBL8679776 | 0.74 | ERN1 (0.68) | ERN1TLR2TLR1TLR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | TLR2, TLR4, TLR3 | ERN1 854/4885TLR2 1/4885TLR1 4/4885 |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | TLR2, TLR4, TLR3 | ERN1 854/4885TLR2 1/4885TLR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.